The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1727
April 28, 2025
View Complete Issue         Table of Contents 2019 
A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine
April 28, 2025 (Issue: 1727)
The FDA has approved Symbravo (Axsome), an oral fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam and the 5-HT1B/1D receptor agonist (triptan) rizatriptan (Maxalt, and generics), for acute treatment of migraine...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine
Article code: 1727b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.